Suitable preclinical models such as Patient derived xenografts (PDX) are needed to evaluate drugs specifically targeting kidney cancer. PDX models are known to be the most predictive preclinical model and provide the an accurate approach to evaluating an agent’s efficacy prior to entering the clinic. The CrownBio kidney cancer PDX collection consists several models, including models from both North American and Asian descent. Learn more about these models in the following publication: -Intra-tumor molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.pdf More
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.